

# Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

NCT06809530

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Guangzhou Medical University
Enrollment	34 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Histologically or cytologically confirmed diagnosis of solid tumors; Cerebrospinal fluid cytopathology is positive.
- Male or female aged between 21 and 75 years; Normal liver and kidney function; WBCe4000/mm<sup>3</sup>, Plte100000/mm<sup>3</sup>.
- No history of severe nervous system disease; No severe dyscrasia.

### Exclusion (4)

- Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.
- Any evidence of extensive and lethal progressive systemic diseases without effective treatment.
- A history of HIV or AIDS, acute or chronic hepatitis B or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years.
- Patients with poor compliance or other reasons that were unsuitable for this study.

## Locations (2 total)

---

The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, Guangdong, China  
The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou, Guangdong, China